245 related articles for article (PubMed ID: 31020628)
1. Asymptomatic hyperuricemia and cardiovascular mortality in patients with chronic kidney disease who progress to hemodialysis.
Petreski T; Ekart R; Hojs R; Bevc S
Int Urol Nephrol; 2019 Jun; 51(6):1013-1018. PubMed ID: 31020628
[TBL] [Abstract][Full Text] [Related]
2. Hyperuricemia and long-term survival in patients with chronic kidney disease undergoing hemodialysis.
Petreski T; Bevc S; Ekart R; Hojs R
Clin Nephrol; 2017 Supplement 1; 88(13):69-72. PubMed ID: 28601125
[TBL] [Abstract][Full Text] [Related]
3. Urate-lowering agents for asymptomatic hyperuricemia in stage 3 - 4 chronic kidney disease: Controversial role of kidney function.
Jeon HJ; Oh J; Shin DH
PLoS One; 2019; 14(6):e0218510. PubMed ID: 31206563
[TBL] [Abstract][Full Text] [Related]
4. [The relationship between hyperuricemia and contrast-induced nephropathy in patients with chronic kidney disease undergoing percutaneous coronary intervention].
Liu YH; Tan N; Liu Y; Ye P; He YT; Ran P; Jiang L
Zhonghua Xin Xue Guan Bing Za Zhi; 2013 Sep; 41(9):740-3. PubMed ID: 24331800
[TBL] [Abstract][Full Text] [Related]
5. The role of uric acid in chronic kidney disease patients.
Hsieh YP; Chang CC; Yang Y; Wen YK; Chiu PF; Lin CC
Nephrology (Carlton); 2017 Jun; 22(6):441-448. PubMed ID: 26610276
[TBL] [Abstract][Full Text] [Related]
6. Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Lee JW; Lee KH
Int Urol Nephrol; 2019 Mar; 51(3):467-473. PubMed ID: 30604229
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for hyperuricemia in congenital heart disease patients and its relation to cardiovascular death.
Rodríguez-Hernández JL; Rodríguez-González F; Riaño-Ruiz M; Martínez-Quintana E
Congenit Heart Dis; 2018 Sep; 13(5):655-662. PubMed ID: 30066365
[TBL] [Abstract][Full Text] [Related]
8. Impact of hyperuricemia and chronic kidney disease on the prevalence and mortality of cardiovascular disease in cancer survivors.
Chen Y; Chen Y; Lin W; Fu L; Liu H; Pu S; Chen H; Yi H; Xue Y
Cancer Med; 2024 May; 13(9):e7180. PubMed ID: 38686569
[TBL] [Abstract][Full Text] [Related]
9. J-shaped mortality relationship for uric acid in CKD.
Suliman ME; Johnson RJ; García-López E; Qureshi AR; Molinaei H; Carrero JJ; Heimbürger O; Bárány P; Axelsson J; Lindholm B; Stenvinkel P
Am J Kidney Dis; 2006 Nov; 48(5):761-71. PubMed ID: 17059995
[TBL] [Abstract][Full Text] [Related]
10. Hyperuricemia and Progression of CKD in Children and Adolescents: The Chronic Kidney Disease in Children (CKiD) Cohort Study.
Rodenbach KE; Schneider MF; Furth SL; Moxey-Mims MM; Mitsnefes MM; Weaver DJ; Warady BA; Schwartz GJ
Am J Kidney Dis; 2015 Dec; 66(6):984-92. PubMed ID: 26209544
[TBL] [Abstract][Full Text] [Related]
11. Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider.
Neri L; Rocca Rey LA; Lentine KL; Hinyard LJ; Pinsky B; Xiao H; Dukes J; Schnitzler MA
Am J Kidney Dis; 2011 Sep; 58(3):398-408. PubMed ID: 21783292
[TBL] [Abstract][Full Text] [Related]
12. Relationship between serum uric acid and all-cause and cardiovascular mortality in patients treated with peritoneal dialysis.
Xia X; He F; Wu X; Peng F; Huang F; Yu X
Am J Kidney Dis; 2014 Aug; 64(2):257-64. PubMed ID: 24176223
[TBL] [Abstract][Full Text] [Related]
13. Uric acid levels and all-cause and cardiovascular mortality in the hemodialysis population.
Latif W; Karaboyas A; Tong L; Winchester JF; Arrington CJ; Pisoni RL; Marshall MR; Kleophas W; Levin NW; Sen A; Robinson BM; Saran R
Clin J Am Soc Nephrol; 2011 Oct; 6(10):2470-7. PubMed ID: 21868616
[TBL] [Abstract][Full Text] [Related]
14. [Uric acid, the kidney and cardiovascular mortality].
Santoro A; Mandreoli M
G Ital Nefrol; 2015; 32 Suppl 62():. PubMed ID: 26005872
[TBL] [Abstract][Full Text] [Related]
15. Effect of Urate Lowering Therapy on Renal Disease Progression in Hyperuricemic Patients with Chronic Kidney Disease.
Kim Y; Shin S; Kim K; Choi S; Lee K
J Rheumatol; 2015 Nov; 42(11):2143-8. PubMed ID: 26428209
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of febuxostat in patients with allopurinol-refractory hyperuricemic chronic kidney disease
.
Kwak CH; Sohn M; Han N; Cho YS; Kim YS; Oh JM
Int J Clin Pharmacol Ther; 2018 Jul; 56(7):321-327. PubMed ID: 29750634
[TBL] [Abstract][Full Text] [Related]
17. Hypomagnesemia is not an independent risk factor for mortality in Japanese maintenance hemodialysis patients.
Mizuiri S; Nishizawa Y; Yamashita K; Naito T; Ono K; Tanji C; Usui K; Doi S; Masaki T; Shigemoto K
Int Urol Nephrol; 2019 Jun; 51(6):1043-1052. PubMed ID: 30977017
[TBL] [Abstract][Full Text] [Related]
18. Association between allopurinol and mortality among Japanese hemodialysis patients: results from the DOPPS.
Tsuruta Y; Nitta K; Akizawa T; Fukuhara S; Saito A; Karaboyas A; Li Y; Port FK; Robinson BM; Pisoni RL; Akiba T
Int Urol Nephrol; 2014 Sep; 46(9):1833-41. PubMed ID: 24908279
[TBL] [Abstract][Full Text] [Related]
19. Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort.
Iseki K; Ikemiya Y; Inoue T; Iseki C; Kinjo K; Takishita S
Am J Kidney Dis; 2004 Oct; 44(4):642-50. PubMed ID: 15384015
[TBL] [Abstract][Full Text] [Related]
20. Ankle-brachial index and cardiovascular mortality in nondiabetic hemodialysis patients.
Bevc S; Purg D; Turnšek N; Hren M; Hojs N; Zorman T; Pečovnik-Balon B; Dvoršak B; Ekart R; Hojs R
Ther Apher Dial; 2013 Aug; 17(4):373-7. PubMed ID: 23931874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
